anti-DOK (CT) antibody product blog
Tags: Antibody; DOK (CT); anti-DOK (CT) antibody;
The DOK (CT) n/a (Catalog #MBS194125) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s DOK (CT) can be used in a range of immunoassay formats including, but not limited to, Immunoblot.Immunoblotting: use at 1:1,000-1:2,000 dilution.
Positive control: Whole cell lysate of Jurkat cells. Researchers should empirically determine the suitability of the DOK (CT) n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Signals from most growth factors and cytokines are transduced by receptor tyrosine kinases or non-receptor tyrosine kinases. Activated tyrosine kinases phosphorylate their substrates which mediates the cellular response to extracellular stimuli. A long-sought major substrate termed p62dok (downstream of tyrosine kinase) for many tyrosine kinases including c-kit, v-abl, v-Fps, v-Src, v-Fms, and activated EGF, PDGF, IGF, VEGF, and insulin receptors, has been identified in human and mouse. Upon phosphorylation, p62dok forms a complex with the ras GTPase-activating protein (RasGAP). p62dok, along with p56dok, represents a new family of RasGAP-binding proteins.
Antigen: Peptide corresponding to aa 425-439 of human p62dok. Stabilizer: None
Preservatives: 0.02% sodium azide.
Dilutions Instructions: Dilute in PBS or medium which is identical to that used in the assay system. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing DOK (CT) are readily searchable from our website. Different antibodies against the same target such as DOK (CT) may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.